ReviewJournal of inflammation research2025
Metabolism-Related Adipokines and Metabolic Diseases: Their Role in Osteoarthritis.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Pathological mechanisms of osteoarthritis in the network of geriatric comorbidities: Emerging insights from organs-crosstalk.Journal of orthopaedic translation · 2026Review
- Osteoarthritis phenotypes: advancing precision medicine through clinical, structural, and molecular stratification.International orthopaedics · 2026Review
- Systemic implications of osteoarthritis: from local degeneration to systemic metabolic Dysregulation.Journal of translational medicine · 2026Review
- RBP4-a risk factor in lipid metabolism-serves as an early diagnostic and prognostic marker of knee osteoarthritis progression.Arthritis research & therapy · 2026Article
- Metabolic dysfunction-associated fatty liver disease and risk of knee osteoarthritis: A prospective cohort study.Clinical and experimental medicine · 2026Article
- Synergistic Effects of Nutritional Formula on Joint Inflammation Through Modulation of Bone Metabolism in Rats.Nutrients · 2026Article
- Comorbidity Between Mood Disorders and Chronic Somatic Diseases, With a Focus on Cardiometabolic Disease, and Its Mechanistic Crosstalk.Depression and anxiety · 2026Review
- Association between gallstones and arthritis in U.S. adults: A cross-sectional NHANES study.Preventive medicine reports · 2026Article
- Integrated multi-omics analysis identifies candidate eRNA-associated signatures shared between osteoarthritis and type 2 diabetes.Frontiers in genetics · 2026Article
- Revisiting the Subtle Relationship Between Metabolic Syndrome and Osteoarthritis.Journal of inflammation research · 2026Review
- Is It Time to Revisit the Role of Interleukin-1 Inhibitors in Osteoarthritis?Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Metabolic-BMI phenotypes as nutritional risk indicators for osteoarthritis: evidence from a prospective cohort of UK adults.Frontiers in nutrition · 2025Article
- Targeting inflammation-metabolism crosstalk: current status and challenges of novel therapeutic strategies for osteoarthritis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) affects several joints but tends to be more prevalent in those that are weight-bearing, such as the knees, which are the most heavily loaded joints in the body. The incidence and disability rates of OA have continued to increase and seriously jeopardise the quality of life of middle-aged and older adults. However, OA is more than just a wear and tear disease; its aetiology is complex, and its pathogenesis is poorly understood. Metabolic syndrome (MetS) has emerged as a critical driver of OA development. This condition contributes to the formation of a distinct phenotype, termed metabolic syndrome-associated osteoarthritis (MetS-OA),which differs from other metabolically related diseases by its unique pathophysiological mechanisms and clinical presentation. As key mediators of MetS, metabolic adipokines such as leptin, lipocalin, and resistin regulate inflammation and bone metabolism through distinct or synergistic signaling pathways. Their modulation of inflammatory responses and bone remodeling processes plays a critical role in the pathogenesis and progression of OA. Due to their central role in regulating inflammation and bone remodeling, metabolic adipokines not only deepen our understanding of MetS-OA pathogenesis but also represent promising targets for novel therapeutic strategies that could slow disease progression and improve clinical outcomes in affected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.